KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Operating Margin (2016 - 2025)

Historic Operating Margin for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to 40.91%.

  • Rigel Pharmaceuticals' Operating Margin rose 155000.0% to 40.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 42.17%, marking a year-over-year increase of 361400.0%. This contributed to the annual value of 13.49% for FY2024, which is 310300.0% up from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' Operating Margin is 40.91%, which was up 155000.0% from 60.09% recorded in Q2 2025.
  • Rigel Pharmaceuticals' Operating Margin's 5-year high stood at 60.09% during Q2 2025, with a 5-year trough of 156.92% in Q1 2022.
  • Over the past 5 years, Rigel Pharmaceuticals' median Operating Margin value was 15.87% (recorded in 2023), while the average stood at 20.8%.
  • Within the past 5 years, the most significant YoY rise in Rigel Pharmaceuticals' Operating Margin was 1090000bps (2022), while the steepest drop was -2084600bps (2022).
  • Rigel Pharmaceuticals' Operating Margin (Quarter) stood at 104.94% in 2021, then surged by 104bps to 4.05% in 2022, then surged by 35bps to 5.49% in 2023, then soared by 426bps to 28.92% in 2024, then skyrocketed by 41bps to 40.91% in 2025.
  • Its Operating Margin was 40.91% in Q3 2025, compared to 60.09% in Q2 2025 and 23.95% in Q1 2025.